The Potential For Litigation In New Era Of Biosimilars

Law360, September 20, 2016

In recent years, there has been widespread litigation related to intellectual property disputes and alleged antitrust violations surrounding generic entry across a wide range of therapeutic classes. For example, over 90 percent of the drugs experiencing initial generic entry between 2011 and 2014 had one or more patent challenges associated with a generic application.